All In Biotech

Drug Trial Radar · NCT07867340

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo Controlled, Single-Dose and Multiple-Ascending Dose Study of Orally Administered LY5625573 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them. Participation in the study will last up to approximately 7 weeks for Part A and 8.5 weeks for Parts B, C, D, and E. For each participant there will be one stay at the clinical research unit (CRU) lasting 5 nights for Part A, 18 nights for Parts B and C, and 17 nights for Parts D and E.

Conditions

  • C-Reactive Protein

Interventions

  • LY5625573Drug

    Administered orally as tablet

  • MidazolamDrug

    Administered orally

  • PlaceboDrug

    Administered orally as tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Follow up (Days 12 and 24)
  2. Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Follow up (Days 12 and 24)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, California · Not yet recruiting

  • Fortrea Clinical Research Unit

    Dallas, Texas · Recruiting

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.